Hydroxy-substituted amino and ammonium derivatives and their medical use
The present invention relates to hydroxy-substituted amino and ammonium derivatives, in particular the compounds of formula (1) or (2), and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.
1. A compound of the following formula 1
wherein:
R 1 is a C 10-20 hydrocarbon group;
R 2 is a C 1-4 alkyl group, and R 3 is —H, a C 1-4 alkyl group or R 3 is absent; or
R 2 and R 3 are mutually linked to form a pyrrolidine ring, a piperidine ring or an azepane ring together with the nitrogen atom X to which they are attached, wherein said pyrrolidine ring, said piperidine ring or said azepane ring is optionally substituted with one or more groups independently selected from —OH, —O(C 1-3 alkyl), —O—C(O)—(C 1-3 alkyl), C 1-3 alkyl, —NH 2 , —NH(C 1-3 alkyl) or —N(C 1-3 alkyl)(C 1-3 alkyl);
R 4 is —H or a C 1-4 alkyl group;
R 5 is a C 2-8 alkyl group, wherein two or more hydrogen atoms of said C 2-8 alkyl group are replaced by —OH, or R 5 is a C 5-7 cycloalkyl group, wherein one ring carbon atom of said C 5-7 cycloalkyl group is optionally replaced by an oxygen atom and wherein one or more hydrogen atoms of said C 5-7 cycloalkyl group are independently replaced by —OH or —CH 2 OH;
X is N + or, if R 3 is absent, X is N; and
p is 1, 2 or 3;
or a pharmaceutically acceptable salt, solvate or thereof.
2. The compound of claim 1 , wherein R 5 is a C 2-8 alkyl group, wherein two or more hydrogen atoms of said C 2-8 alkyl group are replaced by —OH.
3. The compound of claim 1 or 2 , wherein R 5 is, —CH 2 CH(OH)CH 2 OH, —CH 2 CH(OH)CH(OH)CH 2 OH, —CH 2 CH (OH)CH(OH)CH(OH)CH 2 OH, —CH 2 CH(OH)CH(OH)CH(OH)CH(OH)CH 2 OH, or —CH(CH 2 OH)CH(OH)CH(OH)CH(OH)CH 2 OH.
4. The compound of claim 1 , wherein R 4 is methyl.
5. The compound of claim 1 , wherein R 1 is a linear C 10-20 alkyl group, a linear C 10-20 alkenyl group, or a linear C 10-20 alkynyl group.
6. The compound of claim 1 , wherein R 1 is —(CH 2 ) 11 —CH 3 , —(CH 2 ) 13 —CH 3 , or —(CH 2 ) 15 —CH 3 .
7. The compound of claim 1 , wherein R 2 is methyl, and R 3 is —H, methyl or R 3 is absent.
8. The compound of claim 1 , wherein R 2 and R 3 are mutually linked to form a piperidine ring together with the nitrogen atom X to which they are attached, wherein the piperidine ring is optionally substituted with —OH.
9. The compound of claim 1 , wherein p is 1.
10. The compound of claim 1 , wherein the compound is a compound of the following formula 2
wherein:
R 1 is a C 10-20 hydrocarbon group;
R 4 is —H or a C 1-4 alkyl group;
R 5 is a C 2-8 alkyl group, wherein one or more hydrogen atoms of said C 2-8 alkyl group are replaced by —OH, or R 5 is a C 5-7 cycloalkyl group, wherein one ring carbon atom of said C 5-7 cycloalkyl group is optionally replaced by an oxygen atom and wherein one or more hydrogen atoms of said C 5-7 cycloalkyl group are independently replaced by —OH or —CH 20 H;
each R 6 is independently selected from —OH, —O(C 1-3 alkyl), —O—C(O)—(C 1-3 alkyl), C 1-3 alkyl, —NH 2 , —NH(C 1-3 alkyl) or —N(C 1-3 alkyl)(C 1-3 alkyl);
p is 1, 2 or 3;
n is 1, 2, or 3; and
m is an integer from 0 to 4; or
or a pharmaceutically acceptable salt, solvate thereof.
11. The compound of claim 1 , wherein the compound is a compound of the formula 1a, 1b, 1c, or 1d
or a pharmaceutically acceptable salt, solvate thereof.
12. A pharmaceutical composition comprising the compound of claims 1 and a pharmaceutically acceptable excipient.